Table 2 Illustration of expected vision change 3 months after intravitreal triamcinolone acetonide injection for the different patterns of diabetic macular oedema in the presence or absence of epiretinal membrane for different baseline visual acuities.
| Pattern of DME | Baseline Snellen | Baseline logMAR | LogMAR change (−) ERM | LogMAR change (+) ERM | Final Snellen (−) ERM | Final Snellen (+) ERM |
|---|---|---|---|---|---|---|
| SRF | 20/200 | 1 | −0.46 | −0.19 | 20/70 | 20/129 |
| DRT | 20/200 | 1 | −0.29 | −0.02 | 20/103 | 20/191 |
| CME | 20/200 | 1 | −0.14 | 0.13 | 20/145 | 20/270 |
| SRF | 20/80 | 0.60 | −0.34 | −0.21 | 20/36 | 20/49 |
| DRT | 20/80 | 0.60 | −0.04 | −0.04 | 20/54 | 20/73 |
| CME | 20/80 | 0.60 | −0.02 | 0.11 | 20/76 | 20/103 |
| SRF | 20/40 | 0.30 | −0.26 | −0.22 | 20/22 | 20/24 |
| DRT | 20/40 | 0.30 | −0.09 | −0.05 | 20/33 | 20/35 |
| CME | 20/40 | 0.30 | 0.06 | 0.10 | 20/46 | 20/50 |
CME, cystoid macular oedema; DME, diabetic macular oedema; DRT, diffuse macular oedema; ERM, epiretinal membrane; logMAR, logarithm of minimum angle of resolution; SRF, subretinal fluid.